<!DOCTYPE html>
<!-- saved from url=(0062)file:///C:/Users/cva/Downloads/earnings-report-html%20(1).html -->
<html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Latest Quarterly Earnings Summary</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            max-width: 1000px;
            margin: 0 auto;
            padding: 20px;
            color: #333;
        }
        h1 {
            color: #1a5276;
            padding-bottom: 10px;
            border-bottom: 2px solid #1a5276;
        }
        h2 {
            color: #2874a6;
            padding-top: 10px;
            border-top: 1px solid #ddd;
            margin-top: 25px;
        }
        a {
            color: #2874a6;
            text-decoration: none;
        }
        a:hover {
            text-decoration: underline;
        }
        .toc {
            background-color: #f8f9fa;
            padding: 15px;
            border-radius: 5px;
            margin-bottom: 30px;
        }
        .toc ul {
            column-count: 3;
            column-gap: 20px;
            list-style-type: none;
            padding-left: 0;
        }
        .toc li {
            margin-bottom: 8px;
            break-inside: avoid;
        }
        .back-to-top {
            text-align: right;
            margin-top: 15px;
            font-size: 0.9em;
        }
        .company-section {
            margin-bottom: 30px;
            padding-bottom: 20px;
            border-bottom: 1px dashed #ddd;
        }
        .company-header {
            display: flex;
            justify-content: space-between;
            align-items: baseline;
        }
        .report-date {
            font-size: 0.9em;
            color: #666;
        }
        .data-point {
            margin-top: 10px;
        }
        .data-label {
            font-weight: bold;
        }
        @media (max-width: 768px) {
            .toc ul {
                column-count: 1;
            }
        }
    </style>
</head>
<body>
    <h1 id="top">Latest Quarterly Earnings Summary</h1>
    
    <div class="toc">
        <h2>Table of Contents</h2>
        <ul>
            <li><a href="#Abeona-Therapeutics (ABEO)</a></li>
            <li><a href="#agilysys">Agilysys (AGYS)</a></li>
            <li><a href="#alfa-sab">ALFA SAB</a></li>
            <li><a href="#alibaba-group">Alibaba Group (BABA)</a></li>
            <li><a href="#alphawave-ip-group">Alphawave IP Group (AWE.LN)</a></li>
            <li><a href="#amazon">Amazon (AMZN)</a></li>
            <li><a href="#amer-sports">Amer Sports (AS)</a></li>
            <li><a href="#amicus-therapeutics">Amicus Therapeutics (FOLD)</a></li>
            <li><a href="#azelis-group">Azelis Group NV (AZE)</a></li>
            <li><a href="#biomarin-pharmaceutical">BioMarin Pharmaceutical (BMRN)</a></li>
            <li><a href="#champion-homes">Champion Homes (SKY)</a></li>
            <li><a href="#cogent-communications">Cogent Communications (CCOI)</a></li>
            <li><a href="#constellation-energy">Constellation Energy (CEG)</a></li>
            <li><a href="#constellium-se">Constellium SE (CSTM)</a></li>
            <li><a href="#culp-inc">Culp Inc. (CULP)</a></li>
            <li><a href="#dirtt-environmental-solutions">DIRTT Environmental Solutions (DRT.TO/DRTTF)</a></li>
            <li><a href="#estee-lauder">Estée Lauder (EL)</a></li>
            <li><a href="#insmed">Insmed (INSM)</a></li>
            <li><a href="#jdcom">JD.com (JD)</a></li>
            <li><a href="#kia-motors">Kia Motors (000270.KS)</a></li>
            <li><a href="#lb-foster">L.B. Foster (FSTR)</a></li>
            <li><a href="#molina-healthcare">Molina Healthcare (MOH)</a></li>
            <li><a href="#mytheresa">Mytheresa (MYTE)</a></li>
            <li><a href="#norconsult-asa">Norconsult ASA (NORCO)</a></li>
            <li><a href="#pershing-square-holdings">Pershing Square Holdings (PSH)</a></li>
            <li><a href="#quidelortho">QuidelOrtho (QDEL)</a></li>
            <li><a href="#reddit">Reddit (RDDT)</a></li>
            <li><a href="#resideo-technologies">Resideo Technologies (REZI)</a></li>
            <li><a href="#spotify">Spotify (SPOT)</a></li>
            <li><a href="#sterling-infrastructure">Sterling Infrastructure (STRL)</a></li>
            <li><a href="#tapestry">Tapestry (TPR)</a></li>
            <li><a href="#the-realreal">The RealReal (REAL)</a></li>
            <li><a href="#tko-group">TKO Group (TKO)</a></li>
            <li><a href="#tsmc">TSMC (TSM)</a></li>
            <li><a href="#unum-group">Unum Group (UNM)</a></li>
            <li><a href="#united-therapeutics">United Therapeutics (UTHR)</a></li>
        </ul>
    </div>

    <div id="abeona-therapeutics" class="company-section">
        <div class="company-header">
            <h2>Abeona Therapeutics (ABEO)</h2>
            <span class="report-date"><strong>Reported:</strong> November 14, 2024</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q3 2024 reported EPS of -$0.63 with net loss of $30.3 million.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Missed EPS estimates of -$0.40 by 57.5%.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Not specifically mentioned, but the company noted its cash is sufficient to fund operations into 2026.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Stock price declined 2.46% the day after earnings.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="agilysys" class="company-section">
        <div class="company-header">
            <h2>Agilysys (AGYS)</h2>
            <span class="report-date"><strong>Reported:</strong> January 21, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q3 FY2025 EPS of $0.38 with revenue of $69.6 million, representing a 14.9% increase year-over-year.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Beat EPS estimates of $0.34 by 11.76%, but revenue fell short of $73.15 million estimate.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Revised full fiscal year 2025 total revenue guidance downward to $273 million from previous $280-285 million, while maintaining subscription revenue growth forecast of at least 38%.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="alfa-sab" class="company-section">
        <div class="company-header">
            <h2>ALFA SAB</h2>
            <span class="report-date"><strong>Reported:</strong> February 18, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 EBITDA decreased 36% quarter-over-quarter to $177 million. Majority Net Income showed a loss of $311 million. Full year Comparable EBITDA reached $1 billion.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> For 2025, expects normalized revenues of $9.7 billion.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="alibaba-group" class="company-section">
        <div class="company-header">
            <h2>Alibaba Group (BABA)</h2>
            <span class="report-date"><strong>Reported:</strong> February 20, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q3 FY2025 (December quarter) revenue of RMB 280.15 billion ($38.38 billion), up 8% year-over-year. Net income of RMB 48.95 billion ($6.7 billion).
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Revenue slightly exceeded estimates of RMB 279.34 billion. EPS of $2.77 missed estimates of $2.84 by $0.07.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Not specifically mentioned, but CEO noted "revenue growth at Cloud Intelligence Group driven by AI will continue to accelerate."
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Shares rose 9.2% in premarket trading following the announcement. The stock has appreciated by approximately 50% year-to-date on both the New York and Hong Kong exchanges.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="alphawave-ip-group" class="company-section">
        <div class="company-header">
            <h2>Alphawave IP Group (AWE.LN)</h2>
            <span class="report-date"><strong>Reported:</strong> January 21, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 bookings of $185.7 million, up 44% year-over-year, marking the most successful bookings quarter in the company's history. Royalties and silicon orders increased dramatically to $85.8 million from $7.6 million in Q4 2023 (1029% growth). Full-year 2024 bookings exceeded $515 million.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Based on preliminary figures, 2024 revenue expected at the lower end of guidance range of $310-330 million (compared to $321.7 million in 2023). Adjusted EBITDA now expected to exceed $50 million for 2024, down from $63 million in 2023.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> The company stated 2025 will be the year they complete their transition to a semiconductor product company and start generating significant silicon revenue, which they expect to grow substantially in following years.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Shares rose 7.7% to 134.20 pence in London on the day of the announcement (January 21, 2025).
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="amazon" class="company-section">
        <div class="company-header">
            <h2>Amazon (AMZN)</h2>
            <span class="report-date"><strong>Reported:</strong> February 6, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 revenue increased 10% to $187.8 billion. Net income increased to $20.0 billion, or $1.86 per diluted share.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Revenue of $187.8 billion was in line with expectations of $187.4 billion. EPS of $1.86 beat estimates of $1.52 by $0.34 (25.4% above consensus).
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Q1 2025 revenue expected between $151.0 billion and $155.5 billion, below analyst expectations of $158.3 billion.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="amer-sports" class="company-section">
        <div class="company-header">
            <h2>Amer Sports (AS)</h2>
            <span class="report-date"><strong>Reported:</strong> February 25, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 revenue increased 23% to $1.636 billion. Operating profit increased 56% to $471 million with an operating margin of 9.1%.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Not specifically detailed, but CEO expressed confidence in delivering strong results in 2025 and beyond.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned, but analysts have an average price target of $31.54, with a high of $42.00 and a low of $25.00.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="amicus-therapeutics" class="company-section">
        <div class="company-header">
            <h2>Amicus Therapeutics (FOLD)</h2>
            <span class="report-date"><strong>Reported:</strong> February 19, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Full-year 2024 total revenue of $528.3 million, up 33% year-over-year. Galafold generated $458.1 million (+18% YoY) and Pombiliti + Opfolda contributed $70.2 million. GAAP net loss for 2024 was $56.1 million ($0.18 per share), improved from a $151.6 million loss in 2023.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Projects total revenue growth of 17-24% for 2025, with Galafold expected to grow 10-15% and Pombiliti + Opfolda forecasted to increase 65-85%. Anticipates achieving positive GAAP net income during H2 2025 and expects to surpass $1 billion in total sales by 2028.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specified.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="azelis-group" class="company-section">
        <div class="company-header">
            <h2>Azelis Group NV (AZE)</h2>
            <span class="report-date"><strong>Reported:</strong> February 20, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 revenue increased 4.3% to EUR 1,014.2 million, with gross profit up 10.4% to EUR 247.3 million. Full-year 2024 revenue reached EUR 4,214.0 million (+1.5% YoY), with gross profit of EUR 1,031.0 million (+4.8% YoY) and adjusted EBITA of EUR 470.7 million (+0.9% YoY).
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specified.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="biomarin-pharmaceutical" class="company-section">
        <div class="company-header">
            <h2>BioMarin Pharmaceutical (BMRN)</h2>
            <span class="report-date"><strong>Reported:</strong> February 19, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 total revenues of $747 million, up 16% year-over-year. Full-year 2024 total revenues of $2.85 billion, up 18% year-over-year. GAAP Net Income increased by $105 million to $125 million in Q4 2024 compared to the same period in 2023.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Full year 2025 total revenue guidance of $11.75 to $12.0 billion, representing 10% year-over-year growth at the mid-point. The company is on track to deliver its previously targeted total revenues of approximately $4 billion in 2027.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="champion-homes" class="company-section">
        <div class="company-header">
            <h2>Champion Homes (SKY)</h2>
            <span class="report-date"><strong>Reported:</strong> February 4, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q3 FY2025 (quarter ended December 28, 2024) revenue of $644.9 million, up 15.3% year-over-year. Net income of $61.5 million, up 31% from the prior year. Gross profit of $181.0 million, up 28.1%. Adjusted EBITDA of $83.3 million, up 25.7%.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Beat EPS estimates of $0.80 by $0.24 (30%). Revenue of $644.9 million exceeded analyst estimates by 9.2%.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Not specifically mentioned in the earnings release, but the company has a backlog increase of 7.6% compared to December 2023.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Shares rose approximately 18% in the week following the earnings announcement.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="cogent-communications" class="company-section">
        <div class="company-header">
            <h2>Cogent Communications (CCOI)</h2>
            <span class="report-date"><strong>Reported:</strong> February 27, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 service revenue of $252.3 million, down 1.9% sequentially and 7.3% year-over-year. Net loss of $43.3 million or $0.91 per share. EBITDA increased 16.7% sequentially to $41.9 million with a 16.6% margin. Wavelength revenue increased 31.8% sequentially to $7.0 million.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Bottom line beat the Zacks Consensus Estimate by $0.31, but revenue missed by $5 million.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Not specifically mentioned, but the Board approved a quarterly dividend increase to $1.005 per share for Q1 2025 (the company's fiftieth consecutive quarterly dividend increase).
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="constellation-energy" class="company-section">
        <div class="company-header">
            <h2>Constellation Energy (CEG)</h2>
            <span class="report-date"><strong>Reported:</strong> February 18, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 GAAP Net Income of $2.71 per share and Adjusted Operating Earnings of $2.44 per share. Full-year figures reached $11.89 and $8.67 per share respectively, exceeding guidance. Nuclear operating capacity factor of 94.6% for 2024.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Q4 earnings of $2.44 per share surpassed the Zacks Consensus Estimate of $2.19 by 11.4%. Revenue of $5.38 billion missed the Zacks Consensus Estimate of $5.51 billion by 2.4%.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Affirmed full-year 2025 Adjusted Operating Earnings guidance range of $8.90-$9.60 per share. Announced a 25% dividend increase in 2024 with projected 10% growth in 2025.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="constellium-se" class="company-section">
        <div class="company-header">
            <h2>Constellium SE (CSTM)</h2>
            <span class="report-date"><strong>Reported:</strong> February 20, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 revenue of $1.65 billion with EPS of -$0.33.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Missed EPS estimates of $0.04 by $0.36. Revenue of $1.65 billion beat estimates of $1.64 billion by $8.55 million.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="culp-inc" class="company-section">
        <div class="company-header">
            <h2>Culp Inc. (CULP)</h2>
            <span class="report-date"><strong>Reported:</strong> December 4, 2024</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q2 FY2025 consolidated net sales of $55.7 million, down 5.2% compared to prior year. GAAP consolidated loss from operations of $5.4 million (includes $2.8 million in restructuring expense). Non-GAAP loss from operations of $2.6 million.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> Q3 FY2025 consolidated net sales expected to be flat to slightly down sequentially. Company expects positive adjusted EBITDA for the second half of fiscal 2025 and a return to consolidated adjusted operating income sometime in Q4 FY2025.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="dirtt-environmental-solutions" class="company-section">
        <div class="company-header">
            <h2>DIRTT Environmental Solutions (DRT.TO/DRTTF)</h2>
            <span class="report-date"><strong>Reported:</strong> February 26, 2025</span>
        </div>
        <div class="data-point">
            <span class="data-label">Results:</span> Q4 2024 revenue of $48.9 million, down 4% year-over-year but up 13% quarter-over-quarter. Net income of $4.0 million (8.3% margin), compared to $1.0 million (1.9% margin) in Q4 2023. Adjusted EBITDA of $5.5 million (11.2% margin), up from $4.3 million (8.5% margin) in Q4 2023. Full-year 2024 revenue of $174.3 million.
        </div>
        <div class="data-point">
            <span class="data-label">vs Expectations:</span> Revenue was in line with the company's guidance range of $165-175 million. Annual Adjusted EBITDA of $15.4 million exceeded the guidance range of $12-15 million.
        </div>
        <div class="data-point">
            <span class="data-label">Guidance:</span> 2025 revenue expected between $194-209 million with Adjusted EBITDA of $18-25 million. The company plans to increase capital expenditure by more than 50% from 2024 levels.
        </div>
        <div class="data-point">
            <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
        </div>
        <div class="back-to-top">
            <a href="#top">Back to Table of Contents</a>
        </div>
    </div>

    <div id="estee-lauder" class="company-section">
    <div class="company-header">
        <h2>Estée Lauder (EL)</h2>
        <span class="report-date"><strong>Reported:</strong> February 4, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q2 FY2025 net sales declined 6% to $4.0 billion. Operating margin fell to -14.5% from 13.4% year-over-year. Adjusted operating margin contracted 200 basis points to 11.5%, and adjusted diluted EPS decreased to $0.62.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Q3 FY2025 net sales expected to decline 10-8% on an organic basis. Announced restructuring program targeting annual gross benefits of $0.8-1.0 billion, with planned workforce reduction of 5,800-7,000 positions.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="insmed" class="company-section">
    <div class="company-header">
        <h2>Insmed (INSM)</h2>
        <span class="report-date"><strong>Reported:</strong> February 20, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 ARIKAYCE revenue of $104.4 million, contributing to full-year 2024 revenue of $363.7 million (19% annual growth). Reported EPS of -$1.32. Ended 2024 with approximately $1.4 billion in cash, cash equivalents, and marketable securities.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Missed EPS estimates of -$1.17 by $0.15, but revenue of $104.44 million beat estimates of $102.31-$103.83 million.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Reiterated 2025 global ARIKAYCE revenue guidance of $405-$425 million, representing 11-17% year-over-year growth.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned, but as of February 28, 2025, the stock was trading at $80.02, up 2.46%.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="jdcom" class="company-section">
    <div class="company-header">
        <h2>JD.com (JD)</h2>
        <span class="report-date"><strong>Reported:</strong> Not yet reported - scheduled for March 6, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 results will be released on March 6, 2025.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Analysts expect JD.com to post earnings of $0.90 per share and revenue of $332.70 billion for the quarter.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Not applicable as earnings have not been released yet.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not applicable as earnings have not been released yet, but shares opened at $42.53 on February 27, up 6.1%.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="kia-motors" class="company-section">
    <div class="company-header">
        <h2>Kia Motors (000270.KS)</h2>
        <span class="report-date"><strong>Reported:</strong> January 24, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 revenue increased 11.6% to KRW 27.15 trillion with operating profit of KRW 2.72 trillion and a 10% operating margin. Global sales increased 5% to 769,985 units.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Revenue slightly exceeded expectations with a 2.08% surprise.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Targeting 2025 global sales of 3.22 million units, annual revenue of KRW 112.5 trillion, and operating profit of KRW 12.4 trillion with an 11% margin.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="lb-foster" class="company-section">
    <div class="company-header">
        <h2>L.B. Foster (FSTR)</h2>
        <span class="report-date"><strong>Reported:</strong> Not yet reported - scheduled for March 4, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Not yet available.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Analysts expect earnings of $0.29 per share and revenue of $130.80 million for the quarter.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Not yet available.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Currently trading at $26.19, down from a recent high of $30.77.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="molina-healthcare" class="company-section">
    <div class="company-header">
        <h2>Molina Healthcare (MOH)</h2>
        <span class="report-date"><strong>Reported:</strong> February 5, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 revenue of $10.5 billion, up 16% year-over-year. Profit of $251 million, also up 16% year-over-year. Medical loss ratio of 90.2%, up from 89.1% same time last year. Full-year 2024 revenue of $38.6 billion, up 19% from 2023, with net income of $1.2 billion, up 8%.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Beat revenue expectations but missed on earnings. EPS of $5.05 missed consensus estimate of $5.74 by $0.69.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Expects adjusted EPS of at least $24.50 for 2025, which would have been $1 higher if not for implementation costs from recent contract wins.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Stock fell more than 5% in trading the day after earnings.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="mytheresa" class="company-section">
    <div class="company-header">
        <h2>Mytheresa (MYTE)</h2>
        <span class="report-date"><strong>Reported:</strong> February 11, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q2 FY25 net sales growth of 13.4% reaching €223.0 million. GMV growth of 11.9% to €244.7 million. Average Order Value increased 9.5% to €736. Gross Profit margin improved 110 basis points to 50.9%. Adjusted EBITDA of €16.2 million with a 7.3% margin.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Maintained FY25 guidance with expected GMV and Net Sales growth of 7-13% and Adjusted EBITDA margin of 3-5%.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="mytheresa" class="company-section">
    <div class="company-header">
        <h2>Mytheresa (MYTE)</h2>
        <span class="report-date"><strong>Reported:</strong> February 11, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q2 FY25 net sales growth of 13.4% reaching €223.0 million. GMV growth of 11.9% to €244.7 million. Average Order Value increased 9.5% to €736. Gross Profit margin improved 110 basis points to 50.9%. Adjusted EBITDA of €16.2 million with a 7.3% margin.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Maintained FY25 guidance with expected GMV and Net Sales growth of 7-13% and Adjusted EBITDA margin of 3-5%.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="pershing-square-holdings" class="company-section">
    <div class="company-header">
        <h2>Pershing Square Holdings (PSH)</h2>
        <span class="report-date"><strong>Reported:</strong> February 11, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> In 2024, PSH's NAV appreciated 10.2% and total shareholder return was 3.9%. 2025 is off to a good start with NAV appreciation of 8.4% and total shareholder return of 12.9% as of February 10, 2025.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Not specifically mentioned, but the company highlighted its strong performance relative to market indices.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> PSH's discount to NAV widened by 1.6% from 29.6% at the beginning of 2024 to 31.2% at year-end, but has narrowed slightly to 30.2% in early 2025.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

<div id="quidelortho" class="company-section">
    <div class="company-header">
        <h2>QuidelOrtho (QDEL)</h2>
        <span class="report-date"><strong>Reported:</strong> February 12, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 revenue of $708 million, down from $743 million year-over-year. Q4 non-respiratory revenue was $565 million, while respiratory revenue decreased 18% to $143 million. GAAP net loss of $153 million compared to $7 million net income in the prior year.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> 2025 revenue projected between $2.60-2.81 billion with adjusted EBITDA of $575-615 million and adjusted EBITDA margin of 22%.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>    

    <div id="reddit" class="company-section">
    <div class="company-header">
        <h2>Reddit (RDDT)</h2>
        <span class="report-date"><strong>Reported:</strong> February 12, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 revenue of $427.71 million, up 71.25% year-over-year. EPS of $0.36, up 208.82% year-over-year.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Beat revenue estimates of $405.55 million by $22.16 million (5.46%). EPS exceeded estimates of $0.25 by $0.11 (44.23%).
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="resideo-technologies" class="company-section">
    <div class="company-header">
        <h2>Resideo Technologies (REZI)</h2>
        <span class="report-date"><strong>Reported:</strong> February 20, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 net revenue of $1.86 billion, up 21% compared to the prior year period. Gross profit margin was 28.5%, up 100 basis points. Operating profit of $144 million, down 2% from $147 million in the prior year.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Exceeded the high-end of the range for all four key financial metrics according to management.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Q1 2025 revenue expected between $1.72–$1.77 billion with adjusted EBITDA of $150–$170 million. Full-year 2025 revenue projected at $7.285–$7.485 billion.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="champion-homes" class="company-section">
    <div class="company-header">
        <h2>Champion Homes (SKY)</h2>
        <span class="report-date"><strong>Reported:</strong> February 4, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q3 FY2025 (quarter ended December 28, 2024) revenue of $644.9 million, up 15.3% year-over-year. Net income of $61.5 million, up 31% from the prior year. Gross profit of $181.0 million, up 28.1%. Adjusted EBITDA of $83.3 million, up 25.7%.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Beat EPS estimates of $0.80 by $0.24 (30%). Revenue of $644.9 million exceeded analyst estimates by 9.2%.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Not specifically mentioned in the earnings release, but the company has a backlog increase of 7.6% compared to December 2023.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Shares rose approximately 18% in the week following the earnings announcement.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

<div id="spotify" class="company-section">
    <div class="company-header">
        <h2>Spotify (SPOT)</h2>
        <span class="report-date"><strong>Reported:</strong> February 4, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 revenue of €4.2 billion, up 16% year-over-year. Monthly Active Users (MAUs) grew 12% to 675 million, while Premium Subscribers increased 11% to 263 million. Record gross margin of 32.2% (up 555 bps Y/Y) and operating income of €477 million (11.2% margin).
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Not specifically mentioned, but the company highlighted its first full year of operating income at €1.4 billion and record free cash flow of €877 million in Q4.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

<div id="sterling-infrastructure" class="company-section">
    <div class="company-header">
        <h2>Sterling Infrastructure (STRL)</h2>
        <span class="report-date"><strong>Reported:</strong> February 26, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 adjusted EPS of $1.46 with revenue of $498.8 million. Full-year 2024 revenue reached $2.1 billion, a 7% increase, with adjusted EPS growth of 37%.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Beat EPS estimates of $1.29 by $0.17 (13%), but revenue fell short of forecast of $533.43 million.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Not specifically mentioned, but the company highlighted its E-Infrastructure backlog surpassing $1 billion for the first time and announced a strategic shift toward higher-margin projects.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Stock price rose 4.93% in after-hours trading, closing at $121.65 following the earnings release.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="tapestry" class="company-section">
    <div class="company-header">
        <h2>Tapestry (TPR)</h2>
        <span class="report-date"><strong>Reported:</strong> February 6, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q2 FY2025 record revenue of $2.2 billion, representing a 5% increase compared to the prior year. Gross profit of $1.63 billion with a gross margin of 74.4%. Operating income of $493 million (22.4% margin) on a reported basis.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Delivered results that exceeded expectations.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Raised full-year outlook with EPS now expected at $4.85–$4.90, representing 13–14% growth compared to the prior year (up from previous guidance of $4.50–$4.55).
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

<div id="the-realreal" class="company-section">
    <div class="company-header">
        <h2>The RealReal (REAL)</h2>
        <span class="report-date"><strong>Reported:</strong> February 10, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 GMV of $503.5 million and total revenue of $163.1–164.1 million. Adjusted EBITDA of $10.7–11.2 million.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Exceeded previously issued guidance ranges for both GMV and Adjusted EBITDA.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Q1 2025 GMV expected between $484–492 million with Adjusted EBITDA of $3.0–4.5 million. Full-year 2025 GMV projected at $1.96–1.99 billion with Adjusted EBITDA of $20–30 million.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="tko-group" class="company-section">
    <div class="company-header">
        <h2>TKO Group (TKO)</h2>
        <span class="report-date"><strong>Reported:</strong> February 26, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 revenue of $642.2 million with net income of $47.5 million and adjusted EBITDA of $238.1 million.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Beat revenue estimates of approximately $609.6 million by $32.6 million. EPS of $0.35 beat estimates of $0.17 by $0.18.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Full-year 2025 revenue expected between $2.93 billion and $3 billion (excluding future contributions from PBR, IMG, and On Location acquisitions).
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Stock was trading at $159.86, up $3.84 or 2.46% following the earnings announcement.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="tsmc" class="company-section">
    <div class="company-header">
        <h2>TSMC (TSM)</h2>
        <span class="report-date"><strong>Reported:</strong> January 16, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 revenue of NT$868.46 billion ($26.88 billion), up 38.8% year-over-year and 14.3% sequentially. Net income of NT$374.68 billion ($11.59 billion), up 57% year-over-year. Diluted EPS of NT$14.45 ($2.24 per ADR).
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Exceeded LSEG consensus forecasts.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Q1 2025 revenue expected between $25.0–$25.8 billion with gross profit margin between 57–59% and operating profit margin between 46.5–48.5%.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> TSMC's shares rose 3.75% on the day of the announcement.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="unum-group" class="company-section">
    <div class="company-header">
        <h2>Unum Group (UNM)</h2>
        <span class="report-date"><strong>Reported:</strong> February 4, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Q4 2024 net income of $348.7 million ($1.92 per diluted common share).
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> EPS of $2.03 missed analysts' consensus estimates of $2.14 by $0.11.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Provided FY 2025 EPS guidance of $9.12–$9.45, compared to the consensus estimate of $9.10.
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results, but as of February 28, the stock is trading at $81.76, up 5.79%.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>

    <div id="united-therapeutics" class="company-section">
    <div class="company-header">
        <h2>United Therapeutics (UTHR)</h2>
        <span class="report-date"><strong>Reported:</strong> February 28, 2025</span>
    </div>
    <div class="data-point">
        <span class="data-label">Results:</span> Record revenue for the third consecutive year with nearly 24% growth over 2023. Strong performance across product lines with Tyvaso revenue increasing 19% year-over-year for Q4, Orenitram growing 28%, Remodulin up 17%, and Unituxin revenue increasing by 25%.
    </div>
    <div class="data-point">
        <span class="data-label">vs Expectations:</span> Not specifically mentioned in the search results.
    </div>
    <div class="data-point">
        <span class="data-label">Guidance:</span> Aims to maintain double-digit revenue growth through the mid-2020s, with potential inflections expected upon the anticipated approvals of Ralinepag and inhaled treprostinil for idiopathic pulmonary fibrosis (IPF).
    </div>
    <div class="data-point">
        <span class="data-label">Stock Reaction:</span> Not specifically mentioned in the search results.
    </div>
    <div class="back-to-top">
        <a href="#top">Back to Table of Contents</a>
    </div>
</div>








    
